文献速递其他结缔组织病

系统性硬化症冠状动脉微血管功能障碍:PET衍生心肌血流储备的启示

Coronary microvascular dysfunction in systemic sclerosis: insights from PET-derived myocardial flow reserve.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

本研究在耶鲁纽黑文医院回顾性纳入67例系统性硬化症(SSc)患者并与201例无自身免疫风湿病对照按3:1匹配,采用动态82铷PET心肌灌注成像评估心肌血流储备(MFR)。SSc患者静息心肌血流量较高而MFR较低,多变量分析显示霉酚酸酯(MMF)使用与异常MFR风险降低相关,而钙通道阻滞剂和他汀类与风险升高相关。

要点

  • SSc患者MFR低于匹配对照,提示冠状动脉微血管功能障碍普遍存在。
  • MMF使用与异常MFR风险降低相关,但回顾性设计需谨慎解读。
  • PET衍生MFR可作为SSc血管受累的无创标志物,有待前瞻性验证。

核心结论

  • PET心肌灌注成像显示SSc患者MFR降低,提示冠状动脉微血管功能障碍。
  • MMF使用与异常MFR风险降低相关,但回顾性设计需谨慎解读。
  • PET衍生MFR可能作为SSc血管受累的无创标志物,有待前瞻性验证。

研究设计与样本

  • 回顾性研究,纳入2016年7月至2025年4月在耶鲁纽黑文医院行动态82铷PET心肌灌注成像的SSc患者67例。
  • 对照为无自身免疫风湿病者201例,按年龄、性别、BMI和心血管合并症以3:1匹配。
  • 异常MFR定义为<2.0。

主要发现

  • SSc组静息心肌血流量为1.14(IQR 0.91-1.39)ml/g/min,高于对照组的1.00(IQR 0.78-1.25),P=0.01。
  • SSc组MFR为2.17(IQR 1.84-2.57),低于对照组的2.44(IQR 1.96-2.96),P=0.01。
  • 负荷心肌血流量两组相似:SSc组2.47(IQR 1.99-2.82)vs 对照组2.43(IQR 1.91-3.04),P=0.85。
  • 多变量分析显示MMF使用与异常MFR风险降低相关(OR 0.09 [95%CI 0.01-0.56],P=0.017)。
  • 钙通道阻滞剂(OR 7.77 [95%CI 1.93-42.53],P=0.008)和他汀类(OR 7.14 [95%CI 1.86-36.87],P=0.008)与异常MFR风险升高相关。

关键数值与推荐

  • 异常MFR定义为<2.0。
  • SSc队列67例中87%为女性,年龄61±11岁,21%为弥漫性皮肤型SSc,SSc病程12±10年。

临床怎么用

  • PET衍生MFR可用于无创评估SSc患者冠状动脉微血管功能障碍。
  • MMF使用与较低异常MFR风险相关,但需结合回顾性设计局限谨慎看待。
  • 钙通道阻滞剂和他汀类与异常MFR风险升高相关,其临床意义需进一步研究。

局限性

  • 回顾性设计限制了治疗相关关联的因果推断。
  • 单中心研究,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Cardiovascular death is the second leading cause in systemic sclerosis (SSc), with coronary microvascular dysfunction (CMVD) playing a key role. PET-derived myocardial blood flow (MBF) and flow reserve (MFR) offer a validated, non-invasive way to assess CMVD. We studied the prevalence of impaired MFR in SSc and its association with vasodilator or immunomodulatory therapy. METHODS: SSc patients who underwent dynamic 82-Rubidium PET myocardial perfusion imaging (MPI) at Yale New Haven Hospital (July 2016 to April 2025) were studied. Patients were matched 3:1 with controls without autoimmune rheumatologic disease based on age, sex, BMI and cardiovascular comorbidities. Abnormal MFR was defined as <2.0. RESULTS: The cohort included 67 SSc patients (87% female, age: 61 ± 11 years, 21% diffuse cutaneous SSc, SSc duration: 12 ± 10 years) and 201 controls. Rest MBF was higher in SSc (1.14 [IQR 0.91-1.39] ml/g/min) vs controls (1.00 [IQR 0.78-1.25]; P = 0.01), while MFR was lower (2.17 [IQR 1.84-2.57] vs 2.44 [IQR 1.96-2.96]; P = 0.01). Stress MBF was similar (2.47 [IQR 1.99-2.82] vs 2.43 [IQR 1.91-3.04]; P = 0.85). Multivariable analysis showed MMF use linked to lower odds of abnormal MFR (OR 0.09 [95% CI 0.01-0.56]; P = 0.017), while calcium channel blockers (OR 7.77 [1.93-42.53]; P = 0.008) and statins (OR 7.14 [1.86-36.87]; P = 0.008) increased odds. CONCLUSIONS: PET MPI reveals reduced MFR in SSc. Treatment associations, including MMF, should be interpreted cautiously given the retrospective design. PET-derived MFR may serve as a non-invasive marker of vascular involvement, warranting prospective validation.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Williams K, Emokpae M, Koyi B, et al. Coronary microvascular dysfunction in systemic sclerosis: insights from PET-derived myocardial flow reserve. Rheumatology (Oxford). 2026. PMID: 42024682. doi:10.1093/rheumatology/keag215

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。